KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Short-term Investments (2018 - 2023)

Historic Short-term Investments for Esperion Therapeutics (ESPR) over the last 6 years, with Q1 2023 value amounting to $17.4 million.

  • Esperion Therapeutics' Short-term Investments fell 7442.4% to $17.4 million in Q1 2023 from the same period last year, while for Mar 2023 it was $17.4 million, marking a year-over-year decrease of 7442.4%. This contributed to the annual value of $42.1 million for FY2022, which is 1656.39% down from last year.
  • As of Q1 2023, Esperion Therapeutics' Short-term Investments stood at $17.4 million, which was down 7442.4% from $42.1 million recorded in Q4 2022.
  • Esperion Therapeutics' 5-year Short-term Investments high stood at $68.1 million for Q1 2022, and its period low was $2.2 million during Q2 2020.
  • Moreover, its 5-year median value for Short-term Investments was $33.3 million (2019), whereas its average is $35.7 million.
  • Per our database at Business Quant, Esperion Therapeutics' Short-term Investments tumbled by 9164.12% in 2020 and then crashed by 1656.39% in 2022.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Short-term Investments stood at $34.7 million in 2019, then plummeted by 93.52% to $2.2 million in 2020, then soared by 2144.82% to $50.4 million in 2021, then dropped by 16.56% to $42.1 million in 2022, then plummeted by 58.59% to $17.4 million in 2023.
  • Its last three reported values are $17.4 million in Q1 2023, $42.1 million for Q4 2022, and $29.9 million during Q3 2022.